SEARCH

SEARCH BY CITATION

References

  • 1
    Carl-McGrath S, Ebert MP, Lendeckel U, Rocken C. Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther. 2007;6:12181226.
  • 2
    Sipahi I, Chou J, Mishra P, et al. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294301.
  • 3
    Opelz G, Dohler B. Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report. Am J Transplant. 2011;11:24832489.
  • 4
    Rahbari-Oskoui F. Angiotensin II receptor blockers and risk of cancer: cause for concern? Am J Kidney Dis. 2011;57:710.
  • 5
    McMenamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Cont. 2012;23:221230.
  • 6
    Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010;103:16441648.
  • 7
    Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer. 2012;106:290296.
  • 8
    Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627636.
  • 9
    Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011;7:297313.
  • 10
    Yoon C, Yang HS, Jeon I, et al. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. Can Med Assoc J. 2011;183:E1073E1084.
  • 11
    ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623635.
  • 12
    Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:6582.
  • 13
    Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:10031008.
  • 14
    Liu CY, Hung YT, Chuang YL, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Healthcare Manag. 2006;4:122.
  • 15
    Hall GC, Sauer B, Bourke A, et al. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21:110.
  • 16
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:1518.
  • 17
    Celerier J, Cruz A, Lamande N, et al. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension. 2002;39:224228.
  • 18
    Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 2009;8:16761683.
  • 19
    Fujiyama S, Matsubara H, Nozawa Y, et al. Angiotensin AT (1) and AT (2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res. 2001;88:2229.
  • 20
    Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293299.
  • 21
    Kanehira T, Tani T, Takagi T, et al. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-β-dependent cell growth attenuation. Cancer Res. 2005;65:76607665.
  • 22
    Takagi T, Nakano Y, Takekoshi S, et al. Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis. 2002;23:12351241.
  • 23
    Walther T, Menrad A, Orzechowski HD, et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17:20612067.
  • 24
    Puddefoot JR, Udeozo UKI, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer. 2006;13:895903.
  • 25
    Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107:10281033.
  • 26
    Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 2011;29:30013007.
  • 27
    Chin HJ, Oh SW, Goo HS, et al. Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci. 2011;26:5966.
  • 28
    Morote J, Planas J. Antihypertensive drugs and the risk of prostate cancer. Eur Urol. 2011;60:13091310.
  • 29
    Pasternak B, Svanstrom H, Callreus T, et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:17291736.
  • 30
    Sugiura R, Ogawa H, Oka T, et al. HIJ-CREAT Investigators. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Substudy). Am J Cardiol. 2012;109:576580.
  • 31
    Danaei G, Vander Hoorn S, Lopez AD, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366:17841793.
  • 32
    Weiderpass E. Lifestyle and cancer risk. J Prev Med Public Health. 2010;43:459471.
  • 33
    Li FX, Robson PJ, Chen Y, et al. Prevalence, trend, and sociodemographic association of five modifiable lifestyle risk factors for cancer in Alberta and Canada. Cancer Causes Cont. 2009;20:395407.
  • 34
    Baan R, Grosse Y, Straif K, et al. A review of human carcinogens–part F: chemical agents and related occupations. Lancet Oncol. 2009;10:1143.
  • 35
    Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:18271839.
  • 36
    Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systemic review and meta-analysis. Endocr Pract. 2011;17:616628.
  • 37
    Chiang CJ, Chen YC, Chen CJ, et al. Cancer trends in Taiwan. Jpn J Clin Oncol. 2010;40:897904.
  • 38
    Bhaskaran K, Douglas I, Evans S, et al. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344:e2697.